News

AddToAny

Google+ Facebook Twitter Twitter

Test distinguishes SARS-CoV-2

A tablet-sized device has been developed that can detect multiple COVID-19 antibodies and biomarkers simultaneously.

Initial results show it can distinguish between antibodies produced in response to SARS-CoV-2 and four other coronaviruses with 100% accuracy. The team behind the device are now working to see if the point-of-care device can be used to predict the severity of a COVID-19 infection or a person’s immunity against variants of the virus.

Having also recently shown the same “D4 assay” platform can detect Ebola infections a day earlier than the gold standard polymerase chain reaction (PCR) test, the researchers say the results show how flexible the technology can be.

The platform hinges on a polymer brush coating that stops anything but the desired biomarkers from attaching to the test slide when wet.

bit.ly/2Ue26Sz

 

Image Credit | Duke University

 

Related Articles

Memory B cells protecting against mutant viruses

Specialised memory cells found in our immune system play an important role in our ability to fight virus mutations, such as those produced by the SARS-CoV-2 virus, according to research.

“Recovering from covid can take years”

Two years after infection with COVID-19, half of patients who were admitted to hospital still have at least one symptom, according to the longest follow-up study to date.

Lupus: In search of the elusive mutation

Carola Vinuesa explains her research into lupus and what happened when a TLR7 mutation was introduced to mice using CRISPR gene-editing.

“Diabetes in COVID-19 patients may be transitory”

Many COVID-19 patients newly diagnosed with diabetes during hospital admission may in fact have a temporary form of the disease related to the acute stress of the viral infection, it is claimed.

Top